We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
Read MoreHide Full Article
Denmark-based biotech Genmab A/S (GMAB - Free Report) received Orphan Drug designation for its antibody product candidate, epcoritamab, for treating follicular lymphoma (“FL”) from the FDA.
The orphan drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the United States. The orphan drug designation also includes incentives including tax credits for clinical testing, prescription drug user fee exemptions and a seven-year marketing exclusivity in the event of regulatory approval.
Please note that Genmab is co-developing the candidate with AbbVie (ABBV - Free Report) . Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. AbbVie and Genmab share commercial responsibilities for epcoritamab in the United States and Japan while AbbVie is responsible for other regions.
Genmab and AbbVie are evaluating epcoritamab in three early- to mid-stage clinical studies for treating FL. A phase I/II study — EPCORE — is evaluating a subcutaneous formulation of Genmab and AbbVie’s candidate in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL), which includes diffuse large B-cell Lymphoma (DLCBL), FL, and mantle cell lymphoma (MCL). Another phase I/II study is evaluating the safety and efficacy of epcoritamab in Japanese patients with relapsed/refractory B-NHL. A phase Ib/II study is evaluating epcoritamab in combination with standard of care across different lines of therapy in patients with DLBCL or FL.
Shares of Genmab have declined 19.6% so far this year compared with the industry’s decrease of 19.4%.
Image Source: Zacks Investment Research
We note that epcoritamab has been developed using Genmab’s proprietary DuoBody technology platform. Apart from AbbVie, the company’s technology platform has also attracted J&J (JNJ - Free Report) to sign an agreement. In 2012, J&J and Genmab entered into a partnership for developing bispecific antibodies using the latter’s proprietary DuoBody technology platform. In May 2021, J&J received FDA approval for Rybrevant, developed using Genmab’s DuoBody technology platform, for treating adult patients with non-small cell lung cancer with EGFR mutations. J&J’s Darzalex and Darzalex Faspro have also been developed in partnership with Genmab.
Last year, Genmab’s partner Seagen announced that the FDA had granted accelerated approval to their investigational antibody-drug conjugate, Tivdak (tisotumab vedotin-tftv). Seagen received approval for Tivdak for recurrent/metastatic cervical cancer in adult patients whose disease progressed on or after chemotherapy. Seagen and Genmab continue to evaluate Tivdak as a potential treatment for cervical cancer and other solid tumors in different clinical studies.
Image: Bigstock
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
Denmark-based biotech Genmab A/S (GMAB - Free Report) received Orphan Drug designation for its antibody product candidate, epcoritamab, for treating follicular lymphoma (“FL”) from the FDA.
The orphan drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the United States. The orphan drug designation also includes incentives including tax credits for clinical testing, prescription drug user fee exemptions and a seven-year marketing exclusivity in the event of regulatory approval.
Please note that Genmab is co-developing the candidate with AbbVie (ABBV - Free Report) . Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. AbbVie and Genmab share commercial responsibilities for epcoritamab in the United States and Japan while AbbVie is responsible for other regions.
Genmab and AbbVie are evaluating epcoritamab in three early- to mid-stage clinical studies for treating FL. A phase I/II study — EPCORE — is evaluating a subcutaneous formulation of Genmab and AbbVie’s candidate in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL), which includes diffuse large B-cell Lymphoma (DLCBL), FL, and mantle cell lymphoma (MCL). Another phase I/II study is evaluating the safety and efficacy of epcoritamab in Japanese patients with relapsed/refractory B-NHL. A phase Ib/II study is evaluating epcoritamab in combination with standard of care across different lines of therapy in patients with DLBCL or FL.
Shares of Genmab have declined 19.6% so far this year compared with the industry’s decrease of 19.4%.
Image Source: Zacks Investment Research
We note that epcoritamab has been developed using Genmab’s proprietary DuoBody technology platform. Apart from AbbVie, the company’s technology platform has also attracted J&J (JNJ - Free Report) to sign an agreement. In 2012, J&J and Genmab entered into a partnership for developing bispecific antibodies using the latter’s proprietary DuoBody technology platform. In May 2021, J&J received FDA approval for Rybrevant, developed using Genmab’s DuoBody technology platform, for treating adult patients with non-small cell lung cancer with EGFR mutations. J&J’s Darzalex and Darzalex Faspro have also been developed in partnership with Genmab.
Last year, Genmab’s partner Seagen announced that the FDA had granted accelerated approval to their investigational antibody-drug conjugate, Tivdak (tisotumab vedotin-tftv). Seagen received approval for Tivdak for recurrent/metastatic cervical cancer in adult patients whose disease progressed on or after chemotherapy. Seagen and Genmab continue to evaluate Tivdak as a potential treatment for cervical cancer and other solid tumors in different clinical studies.
Genmab AS Sponsored ADR Price
Genmab AS Sponsored ADR price | Genmab AS Sponsored ADR Quote
Zacks Rank
Genmab currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.